Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Set For Immediate US Launch Of Austedo In Tardive Dyskinesia

Sep 01 2017

• By Emily Hayes

FDA approved background, 3D rendering, blue street sign

Related Content

Neurocrine's US Label For Ingrezza Should Provide Edge Over Teva's Austedo In TD

Apr 13 2017

Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza

Apr 12 2017

Teva’s Austedo Positioned To Compete With A Generic Rival

Apr 04 2017

Teva swoops on Auspex with $3.2bn acquisition

Mar 30 2015

Related Companies

Teva Pharmaceutical Industries Ltd.

H. Lundbeck A/S

Auspex Pharmaceuticals, Inc

Neurocrine Biosciences, Inc.

Medicure Inc.

Synchroneuron, Inc.

Additional Topics

Approvals Regulation Research & Development Neurology BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window